Antitumor effect and cardiotoxicity of a doxorubicin-lecithin association.
A doxorubicin-lecithin preparation was tested in vitro on B16 melanoma and Lewis lung carcinoma cells, and in vivo on C57BL/6 mice inoculated with 3LL cells. Results obtained demonstrated that the preparation possesses the same antitumor activity as doxorubicin. The cardiotoxicity of doxorubicin and of the doxorubicin-lecithin association were studied for 120 days after the end of the treatments in Wistar rats inoculated once a week for 5 weeks with equivalent doses of the drugs. Myocardial lesions were observed in both the groups of animals, but their severity and extent were reduced in rats treated with the doxorubicin-lecithin association, and their onset was also delayed.
Bellelli
A
A
Regina Elena National Cancer Institute, Roma, Italy.
Giomini
M
M
Giuliani
A M
AM
Giustini
M
M
Lorenzon
I
I
Rusconi
V
V
Sezzi
M L
ML
Trotta
E
E
Belleli
L
L
D000818:Animals; D002277:Carcinoma / Q000188:drug therapy*; D009202:Cardiomyopathies / Q000139:chemically induced* / Q000473:pathology; D004317:Doxorubicin / Q000008:administration & dosage*; D004562:Electrocardiography; D008546:Melanoma, Experimental / Q000188:drug therapy*; D051379:Mice; D009206:Myocardium / Q000648:ultrastructure; D010713:Phosphatidylcholines / Q000008:administration & dosage*; D051381:Rats; D014407:Tumor Cells, Cultured / Q000187:drug effects
D010713:Phosphatidylcholines; D004317:Doxorubicin